查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627872

IgA肾臟病治疗的全球市场：预测（2025-2030 年）

IGA Nephropathy Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球IGA肾臟病疾病治疗市场规模预计将从2025年的315,914,000美元成长到2030年的591,844,000美元，复合年增长率为13.38%。

由于肾臟疾病盛行率不断增加，预计未来几年对 IGA肾臟病变治疗的需求将会增加。正在进行研究以开发新的有效治疗方法，预计将在预测期内继续为市场相关人员提供成长机会。

此外，新药的批准和核准、提高人们对 IgA肾臟病认识的大规模宣传活动以及健康检查可能会对市场成长产生积极影响。例如，2022年9月，美国食品药物管理局核准了Eldon Pharmaceutical的临床实验新药（IND）申请，用于评估tegopulvert治疗IgA肾臟病的效果。

此外，Cariditas 将于 2022 年 5 月启动 IgA肾臟病教育计划“IgAN Connect”，为刚刚诊断出 IgA肾臟病的人和患有 IgA肾臟病多年的人提供必要的工具和资讯来源。这些药物的核准和许可，加上 IgA肾臟病的教育计划，预计将为未来几年的 IgA肾臟病市场提供积极的前景。

IGA肾臟病治疗市场的驱动因素

  • 慢性肾臟病盛行率的上升将推动全球市场的成长

慢性肾臟病的增加增加了对 IgA肾臟病治疗的需求并推动市场成长。新型致病机制的开发和强大的创新疗法管线预计将在 IgA肾臟病市场的成长中发挥关键作用。

此外，久坐的生活方式、过度吸烟、饮酒量增加以及肥胖的增加都会导致这种疾病的发病率增加。例如，根据美国疾病管制与预防中心2023年发布的报告，美国慢性肾臟病患者的年龄范围为18岁至44岁之间的总人口的6.30％，以及20岁至44岁之间的12.30％。岁和64肾臟病之间。

IGA肾臟病治疗市场的地域展望

  • 预计北美在预测期内将继续占据显着的市场占有率

从地区来看，IGA肾臟病疾病治疗市场分为北美、南美、欧洲、中东和非洲以及亚太地区。

在预测期内，由于主要区域经济体慢性病盛行率不断上升，北美地区预计将以恆定速度成长，并可能占据重要的市场占有率。根据美国卫生与公共服务部国家糖尿病、消化和肾臟疾病研究所的数据，超过七分之一的美国成年人患有慢性肾臟病(CKD)。

根据美国疾病管制与预防中心的数据，近 14% 的美国人（即 3,550 万人）患有慢性肾臟病。此外，根据同一资讯来源，女性比男性更容易患慢性肾臟病。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中释放新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业和市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022年至2030年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略和市场占有率分析
  • 区域收益成长和预测分析，包括细分市场和国家
  • 公司简介（主要是策略、产品、财务资讯、主要动态等）

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • CXO观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章 IGA肾臟病疾病治疗市场：通过测试

  • 介绍
  • 验血
  • 尿液检查
  • 肾臟测试
  • 碘丘氨酸清除率试验
  • 其他的

第六章 IGA肾臟病疾病治疗市场：依治疗类型

  • 介绍
  • 皮质类固醇
  • 免疫抑制药物
  • ACE抑制剂和白蛋白
  • 改善饮食习惯
  • 治疗

第七章 IGA肾臟病治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 其他的

第八章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作
  • 竞争对手仪表板

第九章 公司简介

  • TRAVERE THERAPEUTICS INC.
  • CALLIDITAS THERAPEUTICS AB
  • Omeros
  • NOVARTIS PHARMACEUTICALS
  • CHINOOK THERAPEUTICS INC
  • VERA THERAPEUTICS, INC
  • Merck KGAA
  • REATA PHARMACEUTICALS INC.
  • IONIS PHARMACEUTICALS
  • Stada Group
简介目录
Product Code: KSI061612300

The IGA nephropathy disease treatment market is projected to grow from US$315.914 million in 2025 to US$591.844 million in 2030 at a CAGR of 13.38%.

The need for IgA nephropathy disease treatment is estimated to grow over the coming years on account of the increasing prevalence of kidney diseases. Research is being conducted to develop new and effective treatment methods and continue to offer growth opportunities for the market players during the forecast period.

Moreover, clearances and approval of new drugs as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups will have a positive impact on the market growth. For instance, the US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.

Additionally, in May 2022, Calliditas launched its educational program on IgA Nephropathy called "IgAN Connect" which will provide necessary tools and sources to people who have either recently been diagnosed with IgA Nephropathy or are living for many years. Such drug approval and clearances coupled with education programs relating to IgA Nephropathy present a positive outlook for the IgA Nephropathy market over the coming years

IGA nephropathy disease treatment market drivers

  • Growing prevalence of chronic kidney disease is driving the market growth globally.

The incidences of chronic kidney diseases are increasing the demand for IgA nephropathy which is boosting the market growth. The development of new pathogenic mechanisms and a strong pipeline of innovative prospective therapeutics are anticipated to both play a significant role in the growth of the IgA Nephropathy market.

In addition, sedentary lifestyles, excessive smoking, increased alcohol consumption, and an increase in obesity all contribute to the disease's rising occurrence. For instance, as per the report of Center for Disease Control and Prevention, published in 2023, the people suffering from CKD in the United States with an age range between 18 to 44 was 6.30% of the overall population of that age range, for people aged between 45-64 was 12.30% and that for 65+ people it was 33.70%, hence the IgA nephropathy disease treatment market is anticipated to experience considerable expansion throughout the projected period.

IGA nephropathy disease treatment market geographical outlook

  • North America will continue to hold a remarkable share of the market during the forecast period.

Geographically, the IGA nephropathy disease treatment market has been segmented into North America, South America, Europe, the Middle East, Africa, and the Asia Pacific.

During the forecast period, the North American region is expected to grow at a constant rate and will constitute a considerable market share fueled by the growing chronic disease prevalence in major regional economies. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults.

And according to the Center For Disease Control and Prevention, nearly 14% of the country's total population or 35.5 million Americans suffer from chronic kidney disease. Moreover, the same source also specified that by gender, women are more prone to be affected by chronic kidney disease as compared to men.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The IGA Nephropathy Disease Treatment Market is analyzed into the following segments:

By Test

  • Blood Test
  • Urine Test
  • Kidney Test
  • Iothalamate Clearence Test
  • Others

By Treatment Type

  • Corticosteroids
  • Immunosuppressive Drugs
  • Ace Inhibitors and Arbs
  • Diet Change
  • Therapy

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TEST

  • 5.1. Introduction
  • 5.2. Blood Test
  • 5.3. Urine Test
  • 5.4. Kidney Test
  • 5.5. Iothalamate Clearance Test
  • 5.6. Others

6. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY TREATMENT TYPE

  • 6.1. Introduction
  • 6.2. Corticosteroids
  • 6.3. Immunosuppressive Drugs
  • 6.4. Ace Inhibitors and Arbs
  • 6.5. Diet Change
  • 6.6. Therapy

7. IGA NEPHROPATHY DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. United Kingdom
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. Israel
    • 7.5.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. Japan
    • 7.6.3. India
    • 7.6.4. South Korea
    • 7.6.5. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. TRAVERE THERAPEUTICS INC.
  • 9.2. CALLIDITAS THERAPEUTICS AB
  • 9.3. Omeros
  • 9.4. NOVARTIS PHARMACEUTICALS
  • 9.5. CHINOOK THERAPEUTICS INC
  • 9.6. VERA THERAPEUTICS, INC
  • 9.7. Merck KGAA
  • 9.8. REATA PHARMACEUTICALS INC.
  • 9.9. IONIS PHARMACEUTICALS
  • 9.10. Stada Group